Cargando…

Impact of Insulin Degludec/Liraglutide Fixed Combination on the Gut Microbiomes of Elderly Patients With Type 2 Diabetes: Results From A Subanalysis of A Small Non-Randomised Single Arm Study

In elderly Type 2 Diabetes (T2D) patients the relationship between the destabilization of gut microbiome and reversal of dysbiosis via glucose lowering drugs has not been explored. We investigated the effect of 6 months therapy with a fixed combination of Liraglutide and Degludec on the composition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizza, Stefano, Pietrucci, Daniele, Longo, Susanna, Menghini, Rossella, Teofani, Adelaide, Piciucchi, Giacomo, Montagna, Martina, Federici, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2023
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017153/ https://www.ncbi.nlm.nih.gov/pubmed/37008061 http://dx.doi.org/10.14336/AD.2023.0118

Ejemplares similares

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Can Gut Microbiota Be a Good Predictor for Parkinson’s Disease? A Machine Learning Approach
por: Pietrucci, Daniele, et al.
Publicado: (2020)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
por: Ericsson, Åsa, et al.
Publicado: (2017)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders
por: Teofani, Adelaide, et al.
Publicado: (2022)

Machine Learning Data Analysis Highlights the Role of Parasutterella and Alloprevotella in Autism Spectrum Disorders
por: Pietrucci, Daniele, et al.
Publicado: (2022)

How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
por: Tibaldi, Joseph, et al.
Publicado: (2020)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
por: Torre, Enrico, et al.
Publicado: (2018)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
por: Janez, Andrej, et al.
Publicado: (2020)

Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson’s Disease
por: Cerroni, Rocco, et al.
Publicado: (2022)

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence
por: Raya, Pedro Mezquita, et al.
Publicado: (2019)

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
por: Wei, Ran, et al.
Publicado: (2023)

Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months
por: Martinka, Emil, et al.
Publicado: (2023)

Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes
por: Longo, Susanna, et al.
Publicado: (2023)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
por: King, Allen B., et al.
Publicado: (2017)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
por: Watada, Hirotaka, et al.
Publicado: (2019)

Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
por: Han, Guangxin, et al.
Publicado: (2022)

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
por: Gough, S. C. L., et al.
Publicado: (2015)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver
por: Menghini, Rossella, et al.
Publicado: (2018)

Decreased IRS2 and TIMP3 Expression in Monocytes From Offspring of Type 2 Diabetic Patients Is Correlated With Insulin Resistance and Increased Intima-Media Thickness
por: Cardellini, Marina, et al.
Publicado: (2011)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
por: Price, Hermione, et al.
Publicado: (2018)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
por: Komatsu, Mitsuhisa, et al.
Publicado: (2021)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
por: Lingvay, Ildiko, et al.
Publicado: (2017)

TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy
por: Casagrande, Viviana, et al.
Publicado: (2021)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
por: Pei, Yu, et al.
Publicado: (2021)

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting
por: Drummond, Russell, et al.
Publicado: (2018)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
por: Cheng, Alice, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mpdf4duv84a0flkbll0g2b8gst